Business
NOTTINGHAM OUTLINE PLANNING APPLICATION SUBMITTED
NOTTINGHAM OUTLINE PLANNING APPLICATION SUBMITTED.
About this update from Conygar Investment Company Plc
[{"type":"text","content":"\n \nRNS Number : 1664T Conygar Investment Company PLC(The) 02 July 2018 \n\n \nFor immediate release\n2 July 2018\nTHE CONYGAR INVESTMENT COMPANY PLC\nNOTTINGHAM OUTLINE PLANNING APPLICATION SUBMITTED\nThe Conygar Investment Company PLC (\"Conygar\"), the property investment and development group, announces that the outline planning application for the mixed use scheme in Nottingham detailed in the 2018 interim report has been submitted. The application is for a scheme of over two million square feet and will include offices, apartments and student housing. \nRobert Ware, Chief Executive of Conygar, commented: \"We are delighted to submit this application after working closely with Nottingham City Council over the past year. We will continue to work hard to advance this project.\"\nEnquiries:\nThe Conygar Investment Company PLC\nRobert Ware: 020 7258 8670\nRoss McCaskill: 020 7258 8670\n \nLiberum Capital Limited (Nominated Adviser and Broker)\nRichard Bootle: 020 3100 2222\nHenry Freeman: 020 3100 2222\n \nTemple Bar Advisory (Public Relations)\nAlex Child-Villiers: 07795 425580\nWill Barker: 020 7002 1080 \n \nThis announcement is released by The Conygar Investment Company PLC and contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 (MAR), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.\n \nFor the purposes of MAR and Article 2 of Commission Implementing Regulation (EU) 2016/1055, this announcement is being made on behalf of the Company by Ross McCaskill, Finance Director.\n\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com. END MSCEAAXFEFLPEAF\n ","length":3559,"tagName":"div"}]